Wegovy Pill vs Foundayo: GLP-1 Pills Compared
For years, the most effective weight-loss medicines came in a pen. That changed in the last ten months. The FDA approved the Wegovy pill (oral semaglutide 25 mg) in December 2025 and Foundayo (orforglipron) on April 1, 2026. Both are once-daily tablets for chronic weight management.
They are not the same drug in a different shape. Wegovy pill is semaglutide, the same peptide as the Wegovy shot, packaged so it can survive the stomach. Foundayo is a small-molecule medicine, not a peptide, built to be swallowed. That difference drives most of what patients care about: how you take it, what it interacts with, and how much weight people lost in trials.
Here is a side-by-side look based on the FDA labels and the pivotal trials, and an honest take on who each pill fits.
Table of Contents
The quick comparison
| Wegovy pill | Foundayo | |
|---|---|---|
| Active drug | Semaglutide (peptide GLP-1 receptor agonist) | Orforglipron (non-peptide, small-molecule GLP-1 receptor agonist) |
| Maker | Novo Nordisk | Eli Lilly |
| FDA approval | December 22, 2025 | April 1, 2026 |
| How often | Once daily | Once daily |
| Food and water rules | Empty stomach in the morning, up to 4 oz of plain water, then wait 30 minutes before food, drinks, or other oral medicines | With or without food, any time of day |
| Starting dose to maintenance | 1.5 mg → 4 mg → 9 mg → 25 mg, stepping up every 30 days | 0.8 mg → 2.5 mg → 5.5 mg, then optionally 9, 14.5, or 17.2 mg, at least 30 days per step |
| Pivotal trial | OASIS 4 (64 weeks, 307 adults) | ATTAIN-1 (72 weeks, 3,127 adults) |
| Average weight loss, all randomized patients | 13.6% vs about 2% with placebo | 11.1–11.2% at the top dose vs 2.1% with placebo |
| Weight-loss indication | Yes | Yes |
| Heart-risk (MACE) reduction indication | Yes, in adults with established cardiovascular disease and obesity or overweight | No |
Trial results come from different studies with different people and lengths, so the numbers above are not a head-to-head comparison.
How each pill works
Both medicines activate the GLP-1 receptor, the same target as Wegovy and Ozempic injections. Activating it slows stomach emptying, increases fullness, and reduces appetite. (Our explainer on how GLP-1 medications work covers this in more depth.)
The difference is chemistry. Semaglutide is a peptide, a small protein. Peptides are normally broken down in the gut, which is why most GLP-1s are injected. The Wegovy pill gets around this with an absorption enhancer, but absorption is sensitive to food and liquid. That is why the dosing rules are strict.
Orforglipron is a non-peptide molecule designed from the start to be absorbed by mouth. It does not need the same fasting window. It is cleared mainly by the liver enzyme CYP3A4, which is why its label has drug-interaction rules that semaglutide's does not.
Weight-loss results from the trials
Wegovy pill: OASIS 4
OASIS 4 enrolled 307 adults with obesity, or overweight plus at least one weight-related condition, without diabetes. Participants took oral semaglutide 25 mg or placebo daily for 64 weeks, along with lifestyle counseling. Average weight loss was 13.6% with the pill versus about 2% with placebo, counting everyone who was randomized. Novo Nordisk reports that people who stayed on treatment lost an average of 16.6%. On the FDA label, about 28% of patients on the pill lost 20% or more of their body weight, compared with about 3% on placebo.
Foundayo: ATTAIN-1
ATTAIN-1 enrolled 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes. They took one of three orforglipron doses or placebo for 72 weeks. At the highest dose, average weight loss was 11.2% versus 2.1% with placebo in the published trial (the FDA label reports 11.1%). Lilly reports 12.4% among people who stayed on treatment. About 18% at the top dose lost 20% or more.
One detail confuses people: the trial paper lists doses of 6, 12, and 36 mg, while the label lists 5.5, 9, and 17.2 mg. The label explains that the trials used an investigational formulation and presents those results as the equivalent doses of the marketed tablet. The top trial dose corresponds to Foundayo 17.2 mg.
A separate trial in people with type 2 diabetes is also on the Foundayo label. Weight loss was smaller there (9.6% at the top dose vs 2.5% with placebo), which is a common pattern with GLP-1 medicines.
What about a head-to-head?
We found no published head-to-head trial of the Wegovy pill (25 mg) against Foundayo for weight loss. Two pieces of evidence get quoted, and both come with an asterisk:
- A Novo Nordisk–funded indirect comparison of OASIS 4 and ATTAIN-1 estimated about 3 percentage points more weight loss with oral semaglutide 25 mg and fewer stops due to side effects. Indirect comparisons adjust for differences between trials but cannot replace a randomized head-to-head study.
- ACHIEVE-3, a Lilly-funded trial in adults with type 2 diabetes, found orforglipron lowered A1C more than oral semaglutide. But the semaglutide doses were 7 mg and 14 mg (the diabetes product, Rybelsus), not the 25 mg Wegovy pill dose.
Our read: on average, the Wegovy pill posted somewhat larger weight loss in its pivotal trial. Foundayo is easier to take. Neither fact settles which one is right for a given person.
Dosing rules: the biggest practical difference
Wegovy pill
- Take it in the morning on an empty stomach with no more than 4 ounces of plain water. No coffee, juice, or other liquids with it.
- Swallow it whole. Do not split, crush, or chew.
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines.
- Start at 1.5 mg and increase every 30 days (4 mg, 9 mg) to the 25 mg maintenance dose.
- Missed a dose? The patient guide says skip it and resume the next day.
- It can raise levels of levothyroxine (thyroid hormone); the label reports a 33% increase in exposure in an interaction study. If you take thyroid medication, make sure your prescriber knows.
Foundayo
- Take it once daily, with or without food, at any time of day. Swallow it whole.
- Start at 0.8 mg, then 2.5 mg, then 5.5 mg, at least 30 days apart. Your prescriber may go up to 9, 14.5, or 17.2 mg based on response and tolerability.
- Missed a dose? Take it as soon as possible, but do not double up. If you miss 7 or more days in a row, the dose usually needs to be stepped back down.
- Drug interactions: some medicines that strongly block or speed up the CYP3A4 liver enzyme change orforglipron levels. Certain combinations should be avoided, and the maximum dose is capped at 9 mg with a strong CYP3A4 inhibitor. Give your prescriber a full medication list, and mention any new prescription you start later.
- Birth control pills: the label advises switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase.
Side effects and safety
Both pills share the GLP-1 class side-effect profile. Stomach symptoms are the most common, mostly mild to moderate and most frequent while the dose is going up.
- Wegovy pill: In OASIS 4, gastrointestinal side effects occurred in 74.0% of people on the pill versus 42.2% on placebo. On the label, about 7% stopped because of side effects, compared with about 6% on placebo. Dysesthesia (unusual skin sensations such as tingling or sensitivity) was reported in 5% on the pill and no one on placebo.
- Foundayo: In the pooled weight-loss trials, nausea affected 26–35% depending on dose (vs 10% with placebo), along with constipation, diarrhea, vomiting, indigestion, and abdominal pain. About 8% stopped treatment because of side effects, versus 3% on placebo. Severe gastrointestinal reactions occurred in about 3% versus 1%.
Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents with GLP-1 drugs, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. (Foundayo's label notes orforglipron is not active in rats or mice, so the rodent finding comes from the drug class; human relevance is unknown for both.) Both list warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with certain diabetes drugs, and aspiration risk during anesthesia. Neither should be used in pregnancy.
For practical tips on managing nausea and knowing when to call, see our GLP-1 side effects guide.
Pills vs injections
| Daily pills (Wegovy pill, Foundayo) | Weekly injections (Wegovy, Zepbound) | |
|---|---|---|
| Needles | None | Small weekly injection |
| Remembering a dose | Every day | Once a week |
| Timing rules | Strict for Wegovy pill; none for Foundayo | Any time of day, with or without meals |
| Top-dose average weight loss in pivotal trials* | 13.6% (Wegovy pill 25 mg, 64 wk); 11.1% (Foundayo 17.2 mg, 72 wk) | 14.9% (Wegovy 2.4 mg, 68 wk); 20.9% (Zepbound 15 mg, 72 wk) |
| Storage | Room-temperature tablets (Wegovy pill must stay in its original bottle) | Refrigerated, with limited time allowed at room temperature |
*Intention-to-treat averages from each product's FDA label. Different trials, so treat these as rough context, not a ranking.
The honest summary: the Wegovy pill performs in the same range as the Wegovy injection, and the Wegovy label allows switching between them. Foundayo trades some average weight loss for convenience. Zepbound (tirzepatide) still has the largest average loss of the four. For more on the two injectable options, see Semaglutide vs Tirzepatide Differences.
Who each pill may fit
These are discussion points, not prescriptions.
The Wegovy pill may suit someone who: - Wants the most weight-loss evidence available in a pill. - Has established heart disease and would benefit from a medication with a cardiovascular risk-reduction indication. - Has a steady morning routine and does not mind waiting 30 minutes for coffee or breakfast. - Already does well on semaglutide injections and wants to stop injecting (the label gives a switching schedule).
Foundayo may suit someone who: - Takes several morning medications, travels a lot, or knows a fasting window would not happen reliably. - Wants an oral option with no food or water rules. - Is not taking medicines with major CYP3A4 interactions, and is comfortable with the birth-control precautions if relevant.
An injection may still be the better fit for someone who: - Wants the largest average weight loss, or has not reached goals on a pill. - Prefers one dose a week to a daily habit.
Eligibility for any of these depends on your health history and goals. Our guide to who qualifies for medical weight loss walks through the basics.
Frequently asked questions
Which pill causes more weight loss?
In their pivotal trials, the Wegovy pill averaged 13.6% weight loss and Foundayo's top dose about 11%, in separate placebo-controlled trials of different lengths. A sponsor-funded indirect comparison favored oral semaglutide by about 3 percentage points. No published head-to-head weight-loss trial exists yet.
Do I have to fast with Foundayo?
No. Foundayo's label says to take it once daily with or without food. The Wegovy pill is the one with the empty-stomach, small-sip-of-water, 30-minute-wait rule.
Can I switch from an injection to a pill?
The Wegovy label gives a switching plan between Wegovy 2.4 mg injection and the 25 mg tablet. The Foundayo label does not include instructions for switching from an injectable GLP-1. Any switch should be planned with your prescriber.
Do I keep the weight off after switching or stopping?
Switching to an effective dose of another GLP-1 is designed to maintain treatment. Stopping is different: in the SURMOUNT-4 trial, people switched from tirzepatide injections to placebo regained much of the weight they had lost. Plan any change with your provider.
Are the pills safer than injections?
Not inherently. They carry the same class warnings and similar stomach side effects. The main differences are how you take them and, for Foundayo, liver-enzyme drug interactions.
The bottom line
GLP-1 pills are a real option now, not a future promise. The Wegovy pill has the stronger average weight-loss result among pills and a heart-risk indication, but it demands a strict morning routine. Foundayo is the easiest GLP-1 to take so far, with somewhat lower average weight loss and drug-interaction rules to check. Injections still lead on average results, especially tirzepatide. The best choice is the one you can take consistently and safely, chosen with a licensed provider who knows your full medication list.
Related reading: Compounded GLP-1s in 2026: The FDA 503B Shift · Retatrutide: Triple-Agonist Results and Timeline · Microdosing GLP-1s: Trend vs. Evidence
Sources
This article is provided for general educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Do not switch, start, or stop a weight-loss medication without talking to your prescriber, and always share your full medication list.